FEATURES

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on Products and Its Myopia Program

NEW YORK—Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, has announced its financial and operating results for the quarter ended March 31, 2024.  Read more...


ClearVision Is Named One of the Best Companies to Work for in New York for Ninth Time

HAUPPAUGE, N.Y.—ClearVision Optical was recognized for the ninth time as one of the Best Companies to Work for in New York by the New York State Society for Human Resource Management (NYS-SHRM) and Best Companies GroupRead more...


Harrow Reports Growth in First Quarter of 2024, Restates Commitment to Building Its Dry Eye Disease Franchise

NASHVILLE, Tenn.—Harrow, a U.S. eyecare pharmaceutical company, (Nasdaq: HROW) has announced its results for the first quarter ended March 31, 2024. In the first quarter of 2024, Harrow recorded revenues of $34.6 million, a 33 percent increase over the $26.1 million realized in the prior-year quarter.  Read more...


MOST READ STORIES

CURRENT
ISSUE

April 2024

April 2024

FEATURED COURSE

20/20 Pro to Pro Continuing Education